EUCTR2014-001571-31-ES进行中（未招募）1 期
A randomized (open-label design), parallel group, multicentre study to evaluate the safety and tolerability of two different doses of Depigoid 34% GrassesMix, 33% Olea europaea and 33% Salsola kali a 3000 DPP/ml in subjects with allergic rhinitis or rhinoconjunctivitis, with or without controlled asthma.
aboratorios LETI, S.L. Unipersonal0 个研究点目标入组 71 人开始时间: 2014年8月11日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 71
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients who have dated and signed informed consent and are able to comply with study procedures.
- •2. Patients aged over 18 years and under 70 years of age at selection visit.
- •3. Has an FEV1 or a PEFR value equal or superior to 80% of predicted normal value at selection Visit.
- •4. Individuals suffering from allergic rhinitis and/or rhinoconjunctivitis for at least the preceding year, with or without controlled asthma, caused by triple sensitization against Grasses, Olea europaea and Salsola kali.
- •- The IgE-mediated sensitization must be verified by the following: Suggestive medical history, and Specific IgE to GrassesMix, Olea europaea and Salsola kali > class II; and positive skin prick test (SPT) to GrassesMix, Olea europaea and
- •Salsola kali.
- •A SPT will be considered positive when it produces a wheal whose diameter is at least 3 mm.
- •- Asthmatic subjects can be included in the trial only if allergic asthma is controlled according to the Global Initiative for Asthma (GINA 2010)
- •- Asthmatic subjects must be stable within 3 months prior to Visit 1 and on a stable inhaled steroid dose within 6 weeks prior to Visit 1 and throughout the study.
- •5. If a female is of non-childbearing potential, the subject must be postmenopausal for at least 1 year or surgically sterile (e.g., bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).
- •6. If a female is of childbearing potential, the subject must be non-lactating and non-pregnant (with a negative pregnancy test result at Visit 1) and must correctly use an effective method of contraception during the study. An effective method of contraception is defined as one that results in a failure rate of less than 1% per year. The following are allowed methods of contraception when used continuously and properly: hormonal contraceptives administered by implant, injection, or orally; complete abstinence; partner?s vasectomy if the female has not more than one partner. Barrier methods (e.g., preservatives) are only considered effective if used together with one of the above.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 71
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 71
排除标准
- •1. Any contraindication for treatment with allergen immunotherapy.
- •2. Subjects with a previous history of anaphylaxis.
- •3. Patients with hospital admission due to asthma exacerbations within 1 year prior to V1.
- •4. Has uncontrolled allergic asthma, according to Global Initiative for Asthma Guidelines (GINA 2014f).
- •5. Acute or chronic infectious conjunctivitis.
- •6. Has acute or chronic inflammatory or infectious airways disease.
- •7. Has chronic structural diseases of the affected organ (e.g. eye, nose, lung).
- •8. History or presence of confirmed or potential diseases of the immune system including autoimmune diseases and immune deficiencies of actual clinical relevance.
- •9. Has any disease that prohibits the use of adrenaline (e.g., hyperthyroidism).
- •10. Has a severe uncontrolled disease that could increase the risk to the subjects while participating in the study, including but not limited to, the following: cardiovascular insufficiency, any severe or unstable lung diseases, endocrine diseases, clinically significant renal or hepatic diseases or haematological disorders.
- •11. Subjects with chronic urticaria.
- •12. Subjects with moderate-severe atopic dermatitis (subjects with a SCORAD value >30 can not participate in the study).
- •13. Has had active malignant disease during the previous 5 years.
- •14. Has a significant abnormal laboratory parameter or alteration in vital signs that could increase the risk to the study patient.
- •15. Has used immunotherapy with allergen extracts from Grasses, Olea europaea or Salsola kali within the last 5 years or is receiving allergen specific immunotherapy with other allergens during the study period.
- •16. Has used systemic and/or topical treatment with beta-blocker drugs within 1 week prior to Visit 2 (first IMP administration).
- •17. Used psychotropic, tricyclic, tetracyclic and MAOI antidepressants within 1 month prior to Visit 1. It will not be allowed to perform a washout period of psychotropic or antidepressants to enter the study because of the risks of interrupting the treatment.
- •18. Used systemic corticosteroids within 3 months prior to Visit 1.
- •19. Treatment with substances interfering with the immune system 2 weeks before Visit 2 (first IMP administration).
- •20. Immunization with prophylactic (bacterial or viral) vaccines within 7 days prior to Visit 2 (first IMP administration). Prophylactic vaccines are allowed during the administration of IMP period provided they are administered at least one week after immunotherapy and the next immunotherapy dose is administered at least 14 days later.
- •21. Exposure to any investigational drug within one month or 6 half lives of the drug (whichever is longer).
- •22. Has abused alcohol, drugs or medications within the past year prior to Visit 1.
- •23. Lack of cooperation or compliance with study procedures.
- •24. Subjects with severe psychiatric, psychological, neurological disorders or mental condition which unable the subject to understand the nature, scope and possible consequences of the study.
研究者
相似试验
尚未招募
1 期
A randomized, open-label, parallel-group, single-dose comparative pharmacokinetics study of a candidate biosimilar WT-1 Trastuzumab with reference product in healthy male subjectsHealthy male volunteersbiosimilarpharmacokineticsafetytrastuzumabTCTR20240704011Chulabhorn Foundation by Chulabhorn Research Institute70
进行中（未招募）
1 期
Efficacy and safety of LNP023 compared with rituximab in subjects with idiopathic membranous nephropathy.Idiopathic Membranous nephropathyMedDRA version: 21.1Level: LLTClassification code 10027170Term: Membranous nephropathySystem Organ Class: 100000004857EUCTR2019-001734-34-NLovartis Pharma AG52
已完成
不适用
comparison of potassium hydroxide and podophyllotoxin in the treatment of molluscum contagiosumCTRI/2018/08/015198Dr Niharika Ranjan Lal40
尚未招募
3 期
A clinical trial to study the effects of RTFIT Tablets (Racemethionine 200 mg + Taurine 500 mg Tablets) in patients with alcoholic liver disease.CTRI/2011/05/001764Zota Healthcare Ltd200
进行中（未招募）
1 期
Efficacy and safety of LNP023 compared with rituximab in subjects with idiopathic membranous nephropathy.Idiopathic Membranous nephropathyMedDRA version: 21.1Level: LLTClassification code 10027170Term: Membranous nephropathySystem Organ Class: 100000004857EUCTR2019-001734-34-DEovartis Pharma AG52